Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.37 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.37 |
| ▸ | ITGAL | P20701 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.34 |
| ▸ | SCD5 | Q86SK9 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15020537 | 0.93 | KDM4E (0.37) | FPR2SCN9AITGB2ICAM1ITGAL | |
| SCHEMBL15020822 | 0.88 | FPR2 (0.41) | FPR2SCN9AITGB2ICAM1ITGAL | |
| SCHEMBL15020601 | 0.88 | ALDH1A1 (0.40) | ITGB2ICAM1ITGALKDM4EALDH1A1 | |
| SCHEMBL15042227 | 0.87 | FPR2 (0.46) | FPR2SCN9AITGB2ICAM1ITGAL | |
| SCHEMBL15021019 | 0.87 | FPR2 (0.46) | FPR2SCN9AITGB2ICAM1ITGAL | |
| SCHEMBL15020570 | 0.87 | FPR2 (0.42) | FPR2SCN9AITGB2ICAM1ITGAL | |
| SCHEMBL15020889 | 0.86 | KDM4E (0.36) | FPR2SCN9AITGB2ICAM1ITGAL | |
| SCHEMBL257696 | 0.83 | ITGB2 (0.40) | FPR2SCN9AITGB2ICAM1ITGAL | |
| SCHEMBL15020670 | 0.81 | LMNA (0.37) | ITGB2ICAM1ITGALKDM4EALDH1A1 | |
| SCHEMBL257516 | 0.81 | ALDH1A1 (0.45) | ITGB2ICAM1ITGALKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975264-B2 | Compound acting as a cannabinoid receptor-1 inhibitor | AMOREPACIFIC CORPORATION (KR) | 2015-03-10 | — | — | US | claimed |
| EP-2617723-A2 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | Amorepacific Corporation (KR) | 2013-07-24 | — | — | EP | claimed |
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | AMOREPACIFIC CORPORATION (KR) | 2013-06-20 | — | — | US | claimed |
| US-8975264-B2 | Compound acting as a cannabinoid receptor-1 inhibitor | AMOREPACIFIC CORPORATION (KR) | 2015-03-10 | — | — | US | disclosed |
| EP-2617723-A2 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | Amorepacific Corporation (KR) | 2013-07-24 | — | — | EP | disclosed |
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | AMOREPACIFIC CORPORATION (KR) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | CNR1, CNR2, GPR18 | FPR2 2908/4885SCN9A 615/4885ITGB2 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.